Senzime Inc. Respiratory Motion

Senzime is a medical technology company founded in 1999 and headquartered in Uppsala, Sweden, specializing in advanced patient monitoring and diagnostic systems for anesthesia and acute care. The company's flagship product, TetraGraph, is an electromyography (EMG)-based neuromuscular blockade monitoring system that provides quantitative train-of-four (TOF) monitoring to optimize intubation conditions, neuromuscular block management, and reversal dosing during surgical anesthesia. TetraGraph has been used to monitor over one million patients worldwide and is trusted by thousands of clinicians. The system delivers real-time, objective measurements of neuromuscular function, enabling safer anesthesia practices, improved patient outcomes, and significant operational efficiencies including documented reductions in anesthesia drug spending. Senzime operates globally through direct sales offices in the US, Sweden, and Germany, supported by an extensive network of distributors across Europe, Asia-Pacific, and North America. Listed on NASDAQ Stockholm (ticker: SEZI), Senzime is committed to advancing the standard of care in perioperative monitoring through evidence-based solutions and comprehensive clinical support.